Overall these data suggest that LARGE overexpression may be of therapeutic benefit to patients affected by a dystroglycanopathy, irrespective of the primary gene defect. Here, LARGE1 is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.